WS16-1 Analysis of Time Trends in Incidence of Cystic Fibrosis in Brittany (western France) 30 Years after Implementation of Newborn Screening in That Area

Objectives: Continuous glucose monitoring (CGM) is validated for detecting dysglycaemia in cystic fibrosis (CF), but whether glycaemic excursions seen on CGM are relevant to the long term microvascular complications of diabetes is not well established.To look at this further, we compared the relationship between markers of dysglycaemia on CGM and renal microvascular disease in CF.Methods: We looked at all individuals undergoing CGM with contemporaneous diabetic nephropathy screening at our large adult CF centre.Raw data from each CGM recording was used to calculate measures of hyperglycaemia, hypoglycaemia and glycaemic variability (EasyGV, Oxford, UK).An assessment of discrimination and diagnostic accuracy was made along with a correlation between albumin-creatinine ratio (ACR) and glycaemic markers.Results: There were 168 CGMs with contemporaneous urinary screening in 85 patients (median age ] and 41/168 (24.4%) had evidence of nephropathy (ACR>3.0)).Patients with nephropathy had worse lung function (median ], p < 0.01).Markers of hyperglycaemia and glycaemic variability but not hypoglycaemia were consistently correlated with ACR, see Table 1. Conclusion:We have shown, for the first time, that dysglycaemia on CGM is relevant to renal microvascular disease in adults with CF.Further work is required to investigate the relative contribution of variability and hyperglycaemia to long term microvascular outcomes.